Phase III IPATunity130 is currently evaluating ipatasertib and paclitaxel for PIK3CA/AKT1/PTEN-altered advanced HER-2- breast cancer (NCT03337724) [277]. This evidence concerns the gene PIK3CA and breast carcinoma.